中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

11 records (took 0.021 seconds)

    HUMAN ANTIBODIES TO PD-L1
    1.
    发明申请
    HUMAN ANTIBODIES TO PD-L1 审中-公开
    人体抗PD-L1抗体

    公开(公告)号：WO2015112805A8

    公开(公告)日：2016-07-28

    申请号：PCT/US2015012595

    申请日：2015-01-23

    Applicant: REGENERON PHARMA

    Inventor： PAPADOPOULOS NICHOLAS J ,  MURPHY ANDREW J ,  THURSTON GAVIN ,  IOFFE ELLA ,  BUROVA ELENA

    IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/30

    CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

    Abstract: The present invention provides antibodies that bind to the T-cell co-inhibitor ligand programmed death-ligandl (PD-L1 ) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to PD-L1. In certain embodiments, the present invention provides multi-specific antigen-binding molecules comprising a first binding specificity that binds to PD-L1 and a second binding specificity that binds to a tumor cell antigen, an infected cell-specific antigen, or a T-cell co-inhibitor. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing PD-L1 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.

    Abstract translation: 本发明提供结合T细胞共抑制剂配体的程序性死亡配体（PD-L1）蛋白的抗体及其使用方法。 在本发明的各种实施方案中，抗体是与PD-L1结合的完全人抗体。 在某些实施方案中，本发明提供了多特异性抗原结合分子，其包含结合PD-L1的第一结合特异性和结合肿瘤细胞抗原的第二结合特异性，感染的细胞特异性抗原或T- 细胞共抑制剂。 在一些实施方案中，本发明的抗体可用于抑制或中和PD-L1活性，从而提供治疗疾病或病症如癌症或病毒感染的方法。

    ANTI-IL-33 ANTIBODIES AND USES THEREOF
    5.
    发明申请
    ANTI-IL-33 ANTIBODIES AND USES THEREOF 审中-公开
    抗IL-33抗体及其用途

    公开(公告)号：WO2014164959A3

    公开(公告)日：2015-02-19

    申请号：PCT/US2014023930

    申请日：2014-03-12

    Applicant: REGENERON PHARMA

    Inventor： MURPHY ANDREW J ,  PAPADOPOULOS NICHOLAS J ,  ORENGO JAMIE M

    IPC: C07K16/24

    CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K39/395 ,  A61K2300/00

    Abstract: The present invention provides antibodies that bind to interleukin-33 (IL-33) and methods of using the same. The invention includes antibodies that inhibit or attenuate IL-33-mediated signaling. The antibodies of the invention may function to block the interaction between IL-33 and ST2. Alternatively, certain antibodies of the invention inhibit or attenuate IL-33-mediated signaling without blocking the IL-33/ST2 interaction. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human IL-33 with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as inflammatory diseases, or allergic diseases.

    Abstract translation: 本发明提供了结合白细胞介素-33（IL-33）的抗体及其使用方法。 本发明包括抑制或减弱IL-33介导的信号传导的抗体。 本发明的抗体可用于阻断IL-33和ST2之间的相互作用。 或者，本发明的某些抗体抑制或减弱IL-33介导的信号传导而不阻断IL-33 / ST2相互作用。 根据本发明的某些实施方案，抗体是以高亲和力结合人IL-33的完全人抗体。 本发明的抗体可用于治疗与IL-33信号传导和/或IL-33细胞表达相关的疾病和病症，例如炎性疾病或过敏性疾病。

    THREAPEUTIC METHODS FOR TREATING VASCULAR EYE DISORDERS WITH DLL4 ANTAGONISTS
    6.
    发明申请
    THREAPEUTIC METHODS FOR TREATING VASCULAR EYE DISORDERS WITH DLL4 ANTAGONISTS 审中-公开
    用DLL4拮抗剂治疗血管性眼病的解决方法

    公开(公告)号：WO2008019144A3

    公开(公告)日：2008-03-27

    申请号：PCT/US2007017546

    申请日：2007-08-07

    Applicant: REGENERON PHARMA ,  WIEGAND STANLEY J ,  PAPADOPOULOS NICHOLAS J ,  LOBOV IVAN B

    Inventor： WIEGAND STANLEY J ,  PAPADOPOULOS NICHOLAS J ,  LOBOV IVAN B

    IPC: A61K39/39 ,  A61K38/18 ,  A61P9/00

    CPC classification number: C07K16/2863 ,  A61K38/1709 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/30

    Abstract: A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. Preferably, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch receptor. In one embodiment, the ischemic or vascular disorder is ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension. In another embodiment, the disease treated is an eye disease or condition such as retinopathy of prematurity, ischemic retinopathy, retinal vein or artery occlusion, diabetic retinopathy, choroidal neovascularization, age related macular degeneration, corneal neovascularization, neovascular glaucoma or corneal transplantation.

    Abstract translation: 一种治疗缺血性或血管疾病的治疗方法，其通过向有需要的受试者施用能够抑制人类δ样配体4（DII4）活性的药剂。 优选地，该试剂是能够抑制DII4与Notch受体结合的抗DII4抗体或抗体片段。 在一个实施方案中，缺血性或血管障碍是缺血性损伤，脑缺血，心脏缺血，影响肢体和其他器官或组织的缺血状况，动静脉畸形，伤口愈合，器官或组织移植，胎盘功能不全，动脉狭窄和闭塞，动脉粥样硬化 ，以及全身或肺动脉高压。 在另一个实施方案中，所治疗的疾病是眼部疾病或病症，例如早产儿视网膜病变，缺血性视网膜病变，视网膜静脉或动脉闭塞，糖尿病性视网膜病变，脉络膜新生血管形成，年龄相关性黄斑变性，角膜新生血管形成，新生血管性青光眼或角膜移植。

    HUMAN ANTIBODIES TO NAV1.7
    8.
    发明申请
    HUMAN ANTIBODIES TO NAV1.7 审中-公开
    人类抗体对NAV1.7

    公开(公告)号：WO2014159595A2

    公开(公告)日：2014-10-02

    申请号：PCT/US2014024336

    申请日：2014-03-12

    Applicant: REGENERON PHARMA

    Inventor： MACDONALD LYNN ,  MURPHY ANDREW J ,  PAPADOPOULOS NICHOLAS J ,  STAHL NEIL ,  ALESSANDRI-HABER NICOLE

    IPC: C07K16/28

    CPC classification number: C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention provides antibodies that bind to the human voltage gated sodium channel designated Nav1.7 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Nav1.7 (hNav1.7). The antibodies of the invention are useful for the treatment of diseases and disorders associated with one or more Nav1.7 biological activities, including the treatment of acute or chronic pain conditions, or inflammatory conditions.

    Abstract translation: 本发明提供了结合指定为Nav1.7的人电压门控钠通道的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人Nav1.7（hNav1.7）结合的完全人抗体。 本发明的抗体可用于治疗与一种或多种Nav1.7生物活性相关的疾病和病症，包括治疗急性或慢性疼痛病症或炎性病症。

Patent Agency Ranking